The stock has doubled in the past 12 months.
Let's check the charts after this biotech reports earnings and snags a new 'buy' recommendation.
Here's where aggressive traders could probe.
Here are our latest price targets.
It appears traders of the railroad's stock have become aggressive buyers rather than aggressive sellers.
Let's see what traders could do now.
Here's my first price target and where traders could risk to.
It looks as though the answer could be yes as the shares of the biopharmaceutical company have built a nice base.
Let's delve into the charts and indicators.
The stock of the identity software firm has found support near its current price in the past, but there is no guarantee that will happen again.